EGFR and neoplasm: Our work here described shows that erlotinib, a small molecule that targets EGFR, can prevent or reduce MSC-promoted metastases after primary tumor resection in an IBC preclinical model, and as such this type of therapy may be best used in patients with MSC-stimulated tumors, as these tumors may be more sensitive to this approach.